Amgen Announces Additional Investment In BeiGene

THOUSAND OAKS, Calif., — Amgen (NASDAQ:AMGN) today announced an additional investment of approximately $421 million in BeiGene‘s registered direct offering of ordinary shares, which maintains Amgen’s current pro rata ownership of BeiGene at approximately 20.3%. This additional investment reflects Amgen’s confidence in the progress the companies are making in their ongoing oncology collaboration in China, the world’s second largest pharmaceutical market.

Scroll Up
error: Content is protected !!